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Summary
Background: Themorbidity andmortality associated with influenza is substantial in children with
asthma. There are no available data on the safety and immunogenicity of influenza vaccine in
children with asthma in Latin America. Furthermore, it is unclear if influenza vaccination may
cause asthma exacerbations.
Methods: We conducted a placebo-controlled trial to investigate the safety and immunogenicity
of an inactivated trivalent split virus influenza vaccine in children with asthma in Mexico. We also
measured the impact of influenza vaccination on pulmonary function tests in this population.
Results: The inactivated influenza vaccine was immunogenic and safe in terms of local and
systemic side effects compared to placebo. We observed no significant impact on pulmonary
function tests among vaccine recipients.
Conclusions: Given the significant morbidity associated with influenza in children, strategies to
promote increased influenza vaccination coverage in this high-risk group in Latin America and
elsewhere are urgently needed.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +1 404 686 5885; fax: +1 404 686 4508.
E-mail address: cfranco@sph.emory.edu (C. Franco-Paredes).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.08.015Introduction
Infections due to influenza virus are considered an important
cause of morbidity and mortality. On average, there are
36 000 influenza-associated deaths and approximatelyPublished by Elsevier Ltd. All rights reserved.
470 A. Pedroza et al.114 000 hospitalizations related to influenza each year in the
USA.1,2 The effects of influenza are felt most at both ends of
the age spectrum, but individuals of any age with chronic
medical illnesses such as asthma or chronic obstructive
pulmonary disease are also subject to a considerable burden
of disease.1—3 In this regard, in Mexico4,5 and in other coun-
tries, influenza is considered a leading cause of acute respira-
tory tract infections that lead to health visits,
hospitalizations, and mortality, particularly among those
with chronic pulmonary and cardiac diseases.1—9
Children typically have the highest attack rate, but the
elderly have the highest rate of complications.7—9 In Mexico,
community-acquired pneumonias and influenza were identi-
fied as the ninth cause of death in all age groups in 1998.8
However, the burden of influenza disease in children in
Mexico has not been determined. A recent report from the
New Vaccine Surveillance Network (NSVN) sponsored by the
Centers for Disease Control and Prevention, Atlanta, GA,
USA, identified that the rates of influenza virus infection
in children less than 5 years of age admitted to the hospital
due to fever or respiratory tract infections are substan-
tial.10,11 These rates were estimated at 4.5 per 1000 for
children up to 5 months of age and almost 1 per 1000 for the
total number of children younger than 5 years of age. This
study confirms the vulnerability of children to influenza
infection and thus the importance of targeting this popula-
tion for vaccination.7,10,11
The negative attitudes that parents and healthcare work-
ers have towards the effectiveness of influenza vaccine act to
reduce vaccine uptake in children.7,12—16 Some of these
attitudes are related to the lack of protection of the vaccine
due to occasional poor match between vaccine and the
circulating influenza virus strains.14—16 In addition, it is
believed that influenza vaccination in children with asthma
is associated with disease exacerbation.17—20 In this regard,
although limited evidence of decrease in pulmonary function
associated with the administration of influenza vaccine has
been identified in some earlier studies,21,22 more recent
trials have not observed these negative effects. Indeed, in
a large controlled trial conducted in adults and children with
asthma, influenza vaccination was demonstrated to be safe in
various ethnic groups living in the USA and in other settings as
well.22
The safety and immunogenicity of influenza vaccines has
not been previously assessed in children with asthma in Latin
America. Thus, we were interested in evaluating safety in
terms of the occurrence of systemic and local adverse events
and the impact on pulmonary function tests, and in deter-
mining the immunogenicity of a trivalent inactivated influ-
enza vaccine in children with asthma in Mexico.
Methods
We conducted a randomized, placebo-controlled, double-
blind clinical trial in 163 subjects (31 in the placebo group
and 132 in the influenza vaccine group). Written informed
consent was obtained from parents or guardians of potential
subjects. The study was approved by the Institutional Review
Board of the Instituto Nacional de Pediatria, Mexico. Children
between 5 and 9 years of age with a diagnosis of mild
intermittent and moderate persistent asthma without ahistory of allergy to egg protein or thimerosal were rando-
mized to receive either placebo or a trivalent inactivated
influenza vaccine. The diagnosis of asthma and its staging was
made according to the following criteria: symptoms of daily
life consistent with asthma (dyspnea on exertion, wheezing),
nocturnal awakenings (number per week), lung function
(forced expiratory volume at 1 second (FEV1) and peak flow
measurements), and medication use to relieve symptoms
(frequency of beta-antagonist use). All individuals were
recruited from the outpatient clinics at the Instituto Nacional
de Pediatria, one of the leading pediatric institutions in
Mexico City and part of the National Institutes of Health.
At the end of the study, children in the placebo group were
also immunized.
Eligible subjects were randomly assigned to receive two
doses of trivalent influenza vaccine at a dose of 15 mg of
hemagglutinin (per strain) or placebo. The trial was con-
ducted during the influenza season in Mexico in 2001—2002,
starting September 1, 2001, and with a follow-up of each
individual for 56 days after the administration of the first
dose of influenza vaccine. Each dose was administered intra-
muscularly in the deltoid muscle; the second dose was
administered 28 days after the first dose. The influenza
vaccine used was the trivalent inactivated influenza vaccine
Fluzone1 (Sanofi Pasteur) with the following purified, frac-
tionated, and inactivated strains (2001—2002 strains): A/
New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2),
and B/Victoria/504/2000. The vaccine product was gener-
ated according to standard techniques. All vaccinations were
administered by a clinician who was not involved in the
assessment of adverse events or the laboratory follow-up,
and the contents of the syringe were shielded from the
subject’s view.
The primary immunological end-point of the trial was the
proportion of subjects in each group according to vaccine or
receipt of placebo in whom a neutralizing antibody titer of
1:40 or greater developed against the strains contained in the
vaccine at day 28 after the administration of the first dose of
the vaccine and at day 28 (day 56 of the study) after the
administration of the second dose of the vaccine.
Laboratory analysis was conducted by hemagglutination
inhibition assays according to established procedures with
the use of horse erythrocytes. After treatment with receptor-
destroying enzyme to remove non-specific inhibitors of agglu-
tination, the serum samples were tested at an initial dilution
of 1:20. Serum samples were tested separately and in dupli-
cate. These assays were performed at the viral laboratory of
the National Institute of Diagnosis and Reference of the
Ministry of Health, Mexico (INDRE) with the use of inactivated
influenza vaccine 2001—2002 strains to measure the titers of
protective antibodies. A titer of 1:40 was considered as
evidence of adequate levels of protection. This viral labora-
tory is part of the FLUNET surveillance system of the World
Health Organization, and viral detection methodologies have
been standardized and have quality certifications on influ-
enza diagnostics.
The primary safety end-points included the occurrence of
local adverse events at the inoculation site (pain, erythema,
induration) and systemic adverse events (malaise, fever,
headache). Evaluation of adverse events was assessed on
days 3—5 (visit 2), and days 3—5 after the administration of
the second dose (visit 4). In addition, measurement of pul-
Table 1 General data.
Placebo n = 31 Influenza vaccine n = 132
Females 10 (32.3%) 50 (37.9%)
Males 21 (67.7%) 82 (62.1%)
Age, years; median (min, max) 7.71 (5.04, 9.98) 7.87 (5.0, 9.99)
Weight, kg; median (min, max) 30.3 (17, 56) 28.3 (12.6, 59)
Height, m; median (min, max) 1.25 (1.03, 1.44) 1.24 (0.91, 1.47)
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expiratory volumes at 1, 2, and 3 seconds (FEV1, FEV2,
and FEV3, respectively) were obtained at baseline (visit
1), at day 5 (visit 2), and at day 5 after the administration
of the second dose (visit 4). The objective was to identify the
proportion of subjects who developed local and systemic side
effects after the first and second dose of the administered
vaccine and also the effects of the vaccine on lung function as
measured by FEV1, FEV2, and FEV3 determinations. Pulmon-
ary function tests were carried out by standardized and
approved spirometric protocols at the pulmonary laboratory
of the institution. All the above data were recorded byTable 2 Description of FEV evolution between visits.
Placebo (n = 31)
Change in FEV1 between visit 1 and visit 2
Increase or stagnation (>0%) 22 (71.0%)
Decrease by less than 15% (>15%) 7 (22.6%)
Decrease by more than 15% (<15%) 2 (6.4%)
Change in FEV1 between visit 1 and visit 4
Increase or stagnation (>0%) 19 (61.3%)
Decrease by less than 15% (>15%) 7 (22.6%)
Decrease by more than 15% (<15%) 5 (16.1%)
Change in FEV2 between visit 1 and visit 2
Increase or stagnation (>0%) 24 (80%)
Decrease by less than 15% (>15%) 4 (13.3%)
Decrease by more than 15% (<15%) 2 (6.7%)
Change in FEV2 between visit 1 and visit 4
Increase or stagnation (>0%) 17 (54.8%)
Decrease by less than 15% (>15%) 10 (32.3%)
Decrease by more than 15% (<15%) 4 (12.9%)
Change in FEV3 between visit 1 and visit 2
Increase or stagnation (>0%) 15 (48.4%)
Decrease by less than 15% (>15%) 9 (29.0%)
Decrease by more than 15% (<15%) 7 (22.6%)
Change in FEV3 between visit 1 and visit 4
Increase or stagnation (>0%) 21 (67.7%)
Decrease by less than 15% (>15%) 3 (9.7%)
Decrease by more than 15% (<15%) 7 (22.6%)
FEV, forced expiratory volume; FEV1, forced expiratory volume at one se
expiratory volume at three seconds.research nurses and physicians who were not aware of the
product administered to the individuals in the study. The
safety analysis was carried out according to the rates of
symptoms reported during the first 5 days after administra-
tion of each vaccine dose.
Statistical analysis was performed to measure the primary
immunologic end-point of the trial through the analysis of the
proportion of subjects in each group in whom a neutralizing
titer of 1:40 or greater developed against the three vaccine
strains contained in Fluzone, A/New Caledonia/20/99
(H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/
2000, at day 28 after the administration of the second doseInfluenza vaccine (n = 132) p-Value (t-test)
75 (56.8%)
46 (34.8%)
11 (8.3%) 0.73
65 (49.2%)
42 (31.8%)
25 (18.9%) 0.72
79 (63.7%)
36 (29.0%)
9 (7.3%) 0.94
70 (53.4%)
41 (31.3%)
20 (15.3%) 0.75
78 (59.1%)
26 (19.7%)
28 (21.2%) 0.87
73 (55.3%)
25 (18.9%)
34 (25.8%) 0.71
cond; FEV2, forced expiratory volume at two seconds; FEV3, forced
Table 3 Immunogenicity of influenza vaccine by virus strain in children with asthma after receiving placebo or influenza vaccine.
Placebo (n = 31) Influenza vaccine (n = 132) p-Value
Titers >1:40 H1N1
Pre-vaccination 7 (22.6%) 23 (17.4%) 0.50
Post first dose 8 (25.8%) 108 (81.8%) <0.01
Post second dose 10 (32.3%) 124 (93.9%) <0.01
Titers >1:40 H3N2
Pre-vaccination 8 (25.8%) 57 (43.2%) 0.07
Post first dose 11 (35.5%) 121 (91.7%) <0.01
Post second dose 12 (38.7%) 127 (96.2%) <0.01
Titers >1:40 B
Pre-vaccination 12 (38.7%) 59 (44.7%) 0.54
Post first dose 14 (45.2%) 122 (92.4%) <0.01
Post second dose 18 (58.1%) 129 (97.7%) <0.01
Hemagglutination titers of H1N1, H3N2, and B vaccine strains were measured 28 days after administration of vaccine or placebo.
472 A. Pedroza et al.of the vaccine. In addition, reactogenicity was assessed after
each vaccination based on local and systemic reaction rates.
In order to help the interpretation, p-values were calculated
using the Chi-square test to compare the rates between each
group. All were conducted with SAS software, version 8.2.
Results
There were no significant differences in gender, age, weight,
height, and severity of asthma between the two groups
(Tables 1 and 2). The primary immunogenicity end-point
chosen for this study was the development of hemagglutina-
tion titers of 1:40 or greater after two doses of vaccine. The
results of immunogenicity testing with the use of hemagglu-
tination inhibition are shown in (Table 3). As expected, the
majority of subjects who received the vaccine had antibody
titer production after the first and second doses of the
vaccine at a titer of >1:40 dilutions for H1N1 ( p < 0.01
compared to placebo recipients), H3N2 ( p < 0.01 compared
to placebo recipients), and influenza B vaccine strains
( p < 0.01 compared to placebo recipients).Table 4 Local adverse reactions after the first dose and the sec
Adverse events Placebo (n = 31)
First dose
Pain 8 (25.8%)
Erythemaa 2 (6.5%)
Indurationa 3 (9.7%)
Total No. 12 (38.7%)
Second dose
Pain 7 (22.6%)
Erythemaa 1 (3.2%)
Indurationa 4 (12.9%)
Total No. 9 (29.0%)
a Any measurable reaction >0 cm.The frequencies of local reactions at the injection site
after each dose were similar between vaccine recipients and
placebo recipients and there were no severe local reactions
reported (Table 4). Reports of local pain were not necessarily
accompanied by objective findings of erythema or induration
at the injection site. Systemic symptoms were present in
both groups after the first and the second dose, but there
were no statistical differences between them. It is important
to note that fever was only observed in the vaccine group, but
was judged not clinically relevant (Table 5).
We observed no statistically significant differences in
FEV1, FEV2, and FEV3 determinations at baseline (visit 1)
and determinations on subsequent visits (visit 2 and visit 4),
between those who received the vaccine compared to the
placebo group (Table 2). There were no significant differ-
ences in change in FEV1 between visits 1 and 2 ( p = 0.73) or
between visits 1 and 4 ( p = 0.72), or in FEV2 between visits 1
and 2 ( p = 0.94) or between visits 1 and 4 (0.75), or in FEV3
between visits 1 and 2 ( p = 0.87) or between visits 1 and 4
( p = 0.71). Tables 6—8 show the FEV1, FEV2, and FEV3
measured at each visit and demonstrate that there were
no differences between visits for all determinationsond dose of placebo or influenza vaccine.
Influenza vaccine (n = 132) p-Value
44 (33.3%) 0.41
6 (4.5%) 0.66
20 (15.2%) 0.43
55 (41.7%) 0.76
40 (30.3%) 0.39
7 (5.3%) 0.63
18 (13.6%) 0.91
46 (34.8%) 0.54
Table 5 Systemic adverse reactions after the first dose and the second dose of placebo or influenza vaccine.
Adverse events Placebo (n = 31) Influenza vaccine (n = 132) p-Value
First dose
Fevera 0 (0%) 3 (2.3%) 0.40
Malaise 5 (16.1%) 8 (6.1%) 0.06
Headache 1 (3.2%) 1 (0.8%) 0.26
Others 6 (19.4%) 16 (12.1%) 0.29
Total No. 9 (29.0%) 21 (15.9%) 0.09
Second dose
Fevera 0 (0%) 1 (0.8%) 0.63
Malaise 1 (3.2%) 4 (3.0%) 0.95
Headache 1 (3.2%) 0 (0.0%) 0.04
Others 6 (19.4%) 27 (20.5%) 0.89
Total No. 8 (25.8%) 25 (18.9%) 0.39
a Axillary temperature 38.0 8C.
Influenza vaccine in children with asthma, Mexico 473( p > 0.05), and only a slight difference between the vaccine
and placebo groups for visit 2.
Discussion
Yearly seasonal influenza vaccination is targeted toward the
prevention of the serious consequences of influenza, which
include severe disease, risk of hospitalization, and death.7
Among children, the administration of influenza vaccine is
associated with fewer outpatient visits, decreasedmorbidity,
and decreased hospitalizations.8,23—26 In addition, influenza
vaccination in children may decrease viral shedding and
therefore may impact the transmission dynamics in the
community.27Table 6 Description of FEV1 by vaccine group and by visit.
Placebo
(n = 31)
Influenza
vaccine
(n = 132)
p-Value
(t-test)
Visit 1
Mean 99.1 94.2 0.16
Median 97 95
(Min, max) (60, 147) (49, 136)
Q1:Q3 88:112 84.5:103.5
Visit 2
Mean 104.5 96.2 0.02
Median 105 96
(Min, max) (73, 150) (48, 140)
Q1:Q3 95:114 83.5:109
Visit 4
Mean 99.9 93.6 0.11
Median 103 94
(Min, max) (32, 150) (42, 147)
Q1:Q3 91:114 81:107
Test of time
effect (p-value)
0.463 0.505
FEV1, forced expiratory volume at one second; Q, quartile.Infection with influenza is a common reason for hospita-
lization in children with asthma since this virus makes chil-
dren and adults with asthma prone to bronchoconstriction
and decreased pulmonary function.28—38 The role of influenza
virus as an inducer of asthma exacerbations has been sug-
gested by the fact that antiviral therapy against influenza
leads to fewer asthma exacerbations.21,30,39 Influenza immu-
nization is considered the most important method to prevent
influenza and its severe complications in this and other high-
risk groups.31—37 Given the worldwide prevalence of asthma,
estimated to be at least 10—15% in the pediatric population,
the impact of influenza infection on patients with asthma is
high.17,22 Despite this important association, only a very
small proportion of patients with asthma receive the influ-
enza vaccine each year.17,24 Some of the obstacles associatedTable 7 Description of FEV2 by vaccine group and by visit.
Placebo
(n = 31)
Influenza
vaccine
(n = 132)
p-Value
(t-test)
Visit 1
Mean 97.1 99.1 0.86
Median 98 94
(Min, max) (61, 144) (49, 782)
Q1:Q3 86:106 84.5:106
Visit 2
Mean 104.8 96.1 0.02
Median 104 97.5
(Min, max) (79, 165) (44, 146)
Q1:Q3 93:113 85:106.5
Visit 4
Mean 100 93.9 0.12
Median 100 94
(Min, max) (64, 162) (39, 144)
Q1:Q3 92:108 81.5:107
Test of time
effect (p-value)
0.218 0.540
FEV2, forced expiratory volume at two seconds.
Table 8 Description of FEV3 by vaccine group and by visit.
Placebo (n = 31) Influenza vaccine (n = 132) p-Value (t-test)
Visit 1
Mean 98.7 90.3 0.12
Median 92 90
(Min, max) (52, 162) (32, 174)
Q1:Q3 70:121 71.5:104.5
Visit 2
Mean 95.8 89.8 0.23
Median 94 98.5
(Min, max) (41, 131) (17, 150)
Q1:Q3 85:112 72.5:110
Visit 4
Mean 98.1 88.5 0.07
Median 90 85.5
(Min, max) (59, 145) (27, 168)
Q1:Q3 76:114 73:105
Test of time effect (p-value) 0.907 0.838
FEV3, forced expiratory volume at three seconds.
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asthma include concerns about the efficacy and safety of the
vaccine.17 In particular, there has been some concern about
the possibility of asthma exacerbations due to the adminis-
tration of the vaccine.17—22
Most of the studies on the safety of influenza vaccine in
individuals with asthma have been retrospective analyses or
systematic reviews that used differentmethodologies for eval-
uating lung function in patients with asthma. Nevertheless,
these studies demonstrate a trend towards a significant reduc-
tion intheriskofasthmaexacerbationswiththeuseof influenza
vaccinewith no evidence of worsening of asthma after vaccine
administration.22While someearly studies suggestedapossible
worsening of lung function associated with the vaccine, more
recent large placebo-controlled trials have demonstrated that
theadministration of influenza vaccine in individuals of all ages
with asthma is safe.21,22 The largest prospective study on the
safety of influenza vaccine demonstrated that while patients
with severe asthma were more likely to have an exacerbation
than thosewith fewer asthma symptoms, therewere no differ-
ences in the frequency of exacerbations of asthma after influ-
enza vaccine in the vaccinees versus placebo.22 Our study also
confirms that vaccination of children with asthma living in
Mexico City with a trivalent inactivated influenza vaccine is
not associated with a significant deterioration in pulmonary
function tests. In Mexico and elsewhere there is an ongoing
need to increase influenza vaccination uptake in patients with
asthma to prevent exacerbation of symptoms and hospitaliza-
tions associated with influenza infection.
While the efficacy of influenza vaccine in populations with
asthma continues to demonstrate variable results, most
international authorities agree that influenza vaccination
is an important preventive component of asthma care.27—
34 Furthermore, health-related quality of life is improved
during virus-positive influenza-related illness in vaccine reci-
pients.35Although vaccination against influenza is recommended
for all patients with asthma, the efficacy of this vaccine in
preventing asthma exacerbations secondary to influenza is
still a matter of debate. It has been suggested that the
absence of a clear efficacy benefit in clinical trials may be
due to the fact that placebo-controlled trials are difficult to
perform in a disease state in which vaccination is widely
recommended and requires a large cohort of patients and
should control for several confounding factors that may
interfere in the data analysis.27—34 Another possible expla-
nation may be due to the concomitant administration of
high-dose inhaled corticosteroids in patients with asthma.
However, despite the use of inhaled steroids, in our findings
the vaccine was demonstrated to be highly immuno-
genic.40,41
Despite the above limitations, it is widely recommended
in official guidelines that influenza vaccine be administered
to patients with asthma.7,17 In addition, better communica-
tion strategies are needed to resolve confusion surrounding
influenza vaccine to improve rates of coverage in high-risk
groups such as children with asthma in subspecialty set-
tings.35 The benefit of influenza vaccine clearly outweighs
any potential concern about reactogenicity and impact on
lung function as shown by our results.7,17
The low overall rates of influenza vaccination among
children with asthma highlight the need for improvement
of coverage rates as a component of asthma care for all
children with asthma. Interventions directed toward parents
and healthcare providers, such as informing them of the
relevance of preventing influenza through vaccination and
also about the safety profile of the vaccine,may help improve
influenza vaccination rates in this high-risk group in Latin
America and elsewhere.
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